Dr. Reddy’s looks to branded generics to drive growth

HYDERABAD, India — In his message to shareholders in the company’s 2015-2016 annual report, Dr. Reddy’s Laboratories chairman K Satish Reddy mentioned a new effort the company would be undertaking in North America — a branded generics platform. In addition to leveraging a pipeline of complex generics across its markets while focusing on OTC, Reddy said the branded generics would be one of the ways the company drives growth in the coming years. 

 

“We are creating a branded generics platform in North America and expanding our biologics play in Russia, CIS and other emerging markets,” he wrote. 

 

The report lists the branded generics under its outlook for FY2017. 

 

“In the absence of unforeseen and adverse events, we expect Dr. Reddy’s to perform marginally better in FY2017 vis-à-vis the current year,” the report said.